Jinwu Financial News | The stock price of China Biopharmaceutical (01177) rose to HK$2.72, up 3.03% in early trading. As of press release, it was HK$2.71, up 2.65%, with a turnover of HK$444.28 million.
The “liraglutide injection” (trade name: Bellerine) developed by the Group has obtained marketing approval from the China National Drug Administration to control blood sugar in adults with type 2 diabetes.
Liraglutide is a long-acting analogue of glucagon-like peptide-1 (GLP-1), which is 97% homologous to natural GLP-1. GLP-1 is an endogenous intestinal insulin hormone that enhances glucose-dependent insulin secretion by islet B cells. In addition to islet cells, GLP-1 receptors are also widely found in organs and tissues such as the gastrointestinal tract, lungs, brain, kidneys, and cardiovascular system.